Rybrevant Faspro, the new subcutaneous version of amivantamab, was approved for patients with a specific form of lung cancer ...

From new imaging and targeted therapies to patient journeys, 2025 highlighted key advances and personal stories in lung ...

Zoldonrasib targets KRAS G12D-mutated non-small cell lung cancer, receiving FDA breakthrough therapy designation for its ...

The new artificial intelligence-based software and robot-assisted biopsy technology helps providers catch and treat lung cancer in its earliest stages.

The field of cancer treatment saw a variety of advancements in 2025, from new dedicated centers to approved treatments to ...

The European Medicines Agency (EMA) recommended eight medicines for approval this month, including two cancer drugs for treating non-small cell lung cancer (NSCLC). The regulatory body's Committee for ...

A study led by researchers at Moffitt Cancer Center found that normal cells surrounding a tumor, known as cancer-associated ...

We currently know that COPD, and specifically emphysema, is not just a lung disease found alongside lung cancer; it increases ...

In Brazil, the early detection of genetic alterations in lung cancer through liquid biopsies could be a valuable tool for ...

Lung cancer patients receiving immunochemotherapy earlier in the day had a 52% lower risk of progression in a new medical ...